Pyxis Oncology Reports Q4 Results, Advances MICVO Program

The latest announcement is out from Pyxis Oncology ( (PYXS) ).

Pyxis Oncology reported a series of clinical and corporate milestones alongside its fourth quarter and full-year 2025 results, released on March 23, 2026, highlighting progress in its MICVO program for recurrent/metastatic head and neck squamous cell carcinoma. The company completed target enrollment in its Phase 1 monotherapy dose expansion study in the first quarter of 2026, plans mid-2026 data readouts incorporating modified weight-based dosing to improve the therapy’s benefit-risk profile, and expects updated combination data with KEYTRUDA in the second half of 2026, underpinned by prior positive response rates and supportive translational findings.

Operationally, Pyxis Oncology secured FDA alignment in late 2025 on the design of a planned pivotal MICVO monotherapy trial, extended its cash runway into the fourth quarter of 2026, and strengthened leadership by appointing veteran biotech executive Thomas Civik as interim CEO and adding senior hires in clinical operations and investor relations. These developments, combined with ongoing and upcoming clinical, translational, and preclinical data presentations, reinforce the company’s bid to establish MICVO as a differentiated treatment in head and neck cancer and bolster its strategic positioning with regulators, partners and investors.

The most recent analyst rating on (PYXS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.

Spark’s Take on PYXS Stock

According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.

The score is held down primarily by weak financial performance (large persistent losses and high cash burn) and a broadly bearish technical setup (below key moving averages with negative MACD). A notable offset is the positive corporate event (strong early clinical data and incremental financing runway), but valuation support is limited given negative earnings and no dividend.

To see Spark’s full report on PYXS stock, click here.

More about Pyxis Oncology

Pyxis Oncology, Inc. is a Boston-based, clinical-stage biotechnology company focused on developing next-generation therapeutics for difficult-to-treat cancers. Its lead program, micvotabart pelidotin (MICVO), is being advanced as both a monotherapy and in combination with KEYTRUDA in recurrent/metastatic head and neck squamous cell carcinoma, positioning the company within the antibody-drug conjugate and immuno-oncology segments.

Average Trading Volume: 827,485

Technical Sentiment Signal: Sell

Current Market Cap: $91.53M

See more insights into PYXS stock on TipRanks’ Stock Analysis page.